{"name":"Valentis","slug":"valentis","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOa1djQ0tKbm5HcGhUd0NmVFFSVXhyMFl4TUVpZ2ZJNmYzMmNQcmxoUjBRZ09XNGl2X2Z5UDdXVWFrMGZQTzdRVHRZX2pXVGxLc1Q1MUpNd2xOdEtjcjlIdG1pMEtmYzkyaThGZE9EWE1xUHZGWGFJbGg2alVBTldUajctbU5vYjVTdGxmUGxkUzVLR1ZtSjZnd2hNTEJ5OWxBNWx3UTVCdk8wbWF1MWZOdVlWb3N0Y2wxS0xoMFlKcUJYSnE1aWEtQ28xblR1REViVE1xdml5Q09GRWY2RzVKNlpQMndmWm5LY2ZXZ2VzNW1ubjkyQ2s2SnJUX1U0UdIBgwJBVV95cUxQSnJiaXZXQW1GUThpYjBtYk81UGx3Ul9ZOEl5dWhhQkUtTGRsMVl0ZWNfbDhWckpDdkJ1R2Q3cHIzQ1dMZkEzRFV2UXcxZjVIbkZJZjZ3TXhvcWw5UkhlYUJObWtMV3R6R1lNWXpQSnU3TnFtTTExWXB0QUdHZW1TQUlRX1p0dlk5ZkowT3Q5WDVVMTJtNEMwY1FIaGplekc3M01yb0JYdFNHQ1lGTzFvM19sWGVUSjh4V2NKMzNJaW5zZU5LOXJIZm9GQ1UtMXNwN3FrU0tYWDh3Z1dmelpCQU41dHJwS2Q4TzRFRWRvZi0zbU92LXVSb0N3dWJ4SG1fNXBR?oc=5","date":"2025-11-17","type":"earnings","source":"The Economic Times","summary":"India’s earnings cycle turns the corner; double-digit growth expected in H2: Jyotivardhan Jaipuria - The Economic Times","headline":"India’s earnings cycle turns the corner; double-digit growth expected in H2: Jyotivardhan Jaipuria","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2019-01-24","type":"pipeline","source":"The Economic Times","summary":"Market's going to be quiet for next few months: Daljeet Singh Kohli, Valentis Advisors - The Economic Times","headline":"Market's going to be quiet for next few months: Daljeet Singh Kohli, Valentis Advisors","sentiment":"neutral"},{"date":"2012-10-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: URIGEN PHARMACEUTICALS, INC. FORM 8-K","headline":"SEC 8-K: URIGEN PHARMACEUTICALS, INC. FORM 8-K","sentiment":"neutral"},{"date":"2012-09-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: URIGEN PHARMACEUTICALS, INC. FORM 8-K","headline":"SEC 8-K: URIGEN PHARMACEUTICALS, INC. FORM 8-K","sentiment":"neutral"},{"date":"2012-08-10","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: URIGEN PHARMACEUTICALS, INC. FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2012-06-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: URIGEN PHARMACEUTICALS, INC. FORM 8-K","headline":"SEC 8-K: URIGEN PHARMACEUTICALS, INC. FORM 8-K","sentiment":"neutral"},{"date":"2012-01-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: URIGEN PHARMACEUTICALS FORM 8-K","headline":"SEC 8-K: URIGEN PHARMACEUTICALS FORM 8-K","sentiment":"neutral"},{"date":"2010-09-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: URIGEN PHARMACEUTICALS, INC. FORM 8-K","headline":"SEC 8-K: URIGEN PHARMACEUTICALS, INC. FORM 8-K","sentiment":"neutral"},{"date":"2010-07-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: URIGEN PHARMACEUTICALS, INC.  FORM 8-K","headline":"SEC 8-K: URIGEN PHARMACEUTICALS, INC.  FORM 8-K","sentiment":"neutral"},{"date":"2010-05-17","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: URIGEN PHARMACEUTICALS, INC FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2010-05-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: URIGEN PHARMACEUTICALS, INC","headline":"SEC 8-K: URIGEN PHARMACEUTICALS, INC","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}